1.46
+0.02(+1.39%)
Currency In USD
Address
855 North Wolfe Street
Baltimore, MD 21205
United States of America
Phone
737-289-0835
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
2
First IPO Date
August 14, 2023
| Name | Title | Pay | Year Born |
| Mr. Erez Aminov | Chief Executive Officer & Chairman | 626,193 | 1979 |
| Ms. Michelle Yanez M.B.A. | Chief Financial Officer, Secretary & Treasurer | 185,121 | 1973 |
| Dr. Itzchak Angel Ph.D. | Chief Scientific Advisor | 0 | N/A |
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland.